[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaginal-dryness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaginal-dryness":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,78,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100641575","veda-study-dhea-vs-estradiol-100641575",false,"NCT07574216","VEDA Study (DHEA vs Estradiol)","The Use of Vaginal Estrogen vs DHEA in Perimenopausal and Menopausal Women","Inclusion Criteria:\n\n* Peri- or post-menopausal status\n* Presence of any genitourinary or vaginal symptom (e.g., dryness, itching, discomfort, dyspareunia)\n* Willingness and ability to use vaginal therapy\n* Ability to provide informed consent\n* English speaker\n* Ages 40-90\n\nExclusion Criteria:\n\n* Use of systemic hormone therapy within the last 6 months\n* Gynecologic malignancy\n* Known allergy to study medications\n* Active vaginal infection at enrollment\n* Prior pelvic radiation",true,"FEMALE","40 Years","90 Years",{"count":21,"type":22},324,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is being done to compare two vaginal treatments, vaginal estrogen and vaginal DHEA, that are used to treat vaginal and urinary symptoms related to menopause. These symptoms may include vaginal dryness, discomfort, painful intercourse, or urinary problems and can affect quality of life and sexual health. Women who choose to participate will be randomly assigned to use one of the two treatments for a set period of time. Participants will complete questionnaires about their symptoms and sexual health and have simple vaginal testing at the beginning and end of the study. The goal of this research is to better understand how these treatments affect vaginal health and sexual function so healthcare providers can make informed treatment decisions and improve care for postmenopausal women.",[28,29,30,31,32,33],"Post-menopause","Pre-menopause","Sexual Function","Menopause","Vaginal Dryness","Painful Intercourse",[35,36],"DHEA","vaginal estrogen","NOT_YET_RECRUITING","2026-06-15",{"date":40,"type":41},"2026-06-17","ACTUAL",{"date":43,"type":22},"2026-06-01",{"date":45,"type":22},"2031-12-31",{"name":47,"class":48},"University of Arizona","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100622640","exploration-of-the-effect-of-a-wheat-polar-lipid-complex-on-vaginal-dryness-in-healthy-postmenopausal-women-100622640","NCT07386249","Exploration of the Effect of a Wheat Polar Lipid Complex on Vaginal Dryness in Healthy Postmenopausal Women","Inclusion Criteria:\n\n* Healthy woman, aged of 45 to 65 years (inclusive)\n* In postmenopause, defined according to the STRAW criteria as the absence of menstrual periods for at least 12 consecutive months\n* Reporting a vaginal dryness intensity score ≥ 4 on a 0-10 Visual Analogue Scale (VAS), and a score ≥ 16 on the Menopause Rating Scale (MRS)\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Stated willingness to maintain their usual life habits (diet, physical activity, alcohol consumption…)\n* Speaking French.\n\nExclusion Criteria:\n\n* Use of systemic hormonal therapy within the past 3 months\n* Use of dietary supplements, herbal products, or over-the-counter remedies intended to alleviate menopausal symptoms within 4 weeks prior to the screening visit (wash-out period ≥ 1 month required)\n* Use of vaginal hormonal formulations within 4 weeks prior to screening\n* History of hormone-dependent cancers\n* History of hysterectomy or bilateral oophorectomy\n* Current alcohol dependence or excessive alcohol consumption exceeding an average of 14 standard drinks per week\n* Current use of illicit drugs or recent history of drug dependence\n* Current or previously diagnosed eating disorders considered likely to impact participant safety or study outcomes\n* Presence of severe or uncontrolled chronic medical conditions, or any acute medical condition judged by the investigator to potentially interfere with the MRS assessment or participant safety\n* Subject participating in another intervention trial","45 Years","65 Years",{"count":58,"type":22},110,[25],"This study aims to explore the positive effect of a dietary supplement composed of wheat polar lipids on vaginal dryness in healthy postmenopausal women",[32,62],"Menopause Symptoms",[31,64,65],"Wheat polar lipids","Vaginal dryness","RECRUITING","2026-04-22",{"date":69,"type":41},"2026-04-23",{"date":71,"type":41},"2026-02-02",{"date":73,"type":22},"2026-11",{"name":75,"class":76},"Seppic","INDUSTRY",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":100,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":77},"100590048","changes-in-the-impact-of-genitourinary-syndrome-of-menopause-with-a-novel-nonhormonal-vulvovaginal-gel-assessed-by-proms-100590048","NCT06962345","Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.","Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs. Phase 2, Single Arm, Interventional, Longitudinal, Clinical Trial. Part of STOP GSM PROJECT.","STOPGSMP","Inclusion Criteria:\n\n* Patient has to have at least one symptom of GSM or suffer from symptoms related to vulvovaginal atrophy (as evidenced by gynecological examination with a Vaginal Health Index ≤15).\n* Patient must be postmenopausal with at least 1 year without a menstrual period.\n* Patient must consider that her quality of life is affected by GSM symptoms\n* Patient not followed due to any gynecological disease.\n* All participants must be able to understand and to fill in the self-reported questionnaires.\n\nExclusion Criteria:\n\n* Patients that do not want to fill the questionnaire, especially the questions that address sexual functioning.\n* Participants that use any oral products containing hormones or estrogen receptor modulators for the past 8 weeks, nor vaginal topical hormone products within 4 weeks, neither prescription nor non-prescription therapies for GSM, including topical vaginal non-hormonal lubricants or moisturizers for the last week.\n* Patients with history of vulvar, vaginal and\u002For cervical malignancy.\n* Patients having received radiotherapy treatment in the pelvic and\u002For genital region.\n* Patients with any type of disease that causes alteration of collagenogenesis.\n* Patients that use cytotoxic drugs leading to mucositis and alterations of tissue regeneration in the last 6 months.\n* Patients having received laser and\u002For radiofrequency treatment for handling genital atrophy or other pelvic floor dysfunctions.\n* Patients with active urinary and\u002For genital tract infection.\n* Patients with history of malignant neoplasm of the urinary system.\n* Patients with severe stress urinary incontinence (Sandvik test score equal to or greater than 8).\n* Patients with diagnosis of pelvic organ prolapse grade III or higher according to the POP-Q classification.\n* Patients with medical or surgery history that, at the investigator's discretion, does not allow participation in the study.\n* Patients with any other condition that, at the investigator's discretion, implies that the patient is unable to understand the implication of participating in the study and\u002For following the established procedures.","70 Years",{"count":88,"type":22},80,[25],"The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the vulvovaginal area. Symptoms of vaginal atrophy will be compared before and after 8 weeks of use of the tested gel with the Day-to-Day Impact of Vaginal Aging (DIVA) PROMs questionnaire to assess changes impact of GSM symptoms.",[92,93,94,95,96,97,98,30,99,32],"Vulvar Atrophy","Vulvovaginal Signs and Symptoms","Genitourinary Syndrome of Menopause","Quality of Life","Menopause Related Conditions","Dyspareunia","Urinary Incontinence, Urgency-frequency","Women´s Health",[94,93,101,95,102,99],"Patient Reported Outcome Measures","Day-to-Day Impact of Vaginal Ageing","2026-03-25",{"date":105,"type":41},"2026-03-30",{"date":107,"type":41},"2024-01-08",{"date":109,"type":22},"2026-12",{"name":111,"class":76},"Mucosa Innovations, S.L.",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":77},"100585285","efficacy-and-safety-of-vaginal-radiofrequency-for-vulvovaginal-atrophy-in-breast-cancer-patients-100585285","NCT06900374","Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients","RF-Vaginale : Randomised Phase III Trial Evaluating the Efficacy and Safety of Vaginal Radiofrequency in the Management of Vulvovaginal Atrophy and Dryness in Patients Treated for Breast Cancer","RF-Vaginale","INCLUSION CRITERIA :\n\n* Patient over 40 years\n* Presenting disabling vaginal dryness symptoms despite well-administered local moisturizing treatment, attested by a vaginal dryness score ≥3\n* Patient undergoing adjuvant treatment for breast cancer\n* Patient treated with aromatase inhibitors +\u002F- LHRH agonist for at least 3 months with a planned remaining duration of at least 12 months\n* Patient affiliated to a social security organization\n* Patient having signed the informed consent for the present study\n\nEXCLUSION CRITERIA:\n\n* Contraindications related to the radiofrequency technique:\n\n  * Ongoing urinary tract infection\n  * Pacemaker\n  * IUD intrauterine device\n  * Pregnancy\n* Mucocutaneous disease with vulvovaginal localization: infection, sore, scleratrophic lichen, psoriasis, eczema, etc.\n* Neurodegenerative disease with perineal involvement\n* Current or recent treatment (within the last 12 months) with other physical methods: vaginal laser, photobiomodulation, PRP injection, hyaluronic acid injection or lipo-modeling.\n* Pregnant or breast-feeding women\n* Patients under guardianship or trusteeship.",{"count":121,"type":22},75,[25],"This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months. The study compares vaginal radiofrequency treatment with non-hormonal hydration therapy in a population of patients undergoing adjuvant hormonal therapy with aromatase inhibitors, with or without LHRH agonists, for breast cancer.\n\nPatients will be randomly assigned to one of two parallel treatment groups until the six-month assessment:\n\nThe first group will receive the reference treatment, which consists of local hydration using a hyaluronic acid-based treatment applied three times a week. Additionally, investigators may incorporate supportive measures at their discretion, such as physiotherapy or vaginal dilators.\n\nThe second group will receive the same reference treatment combined with vaginal radiofrequency therapy. This intervention consists of three sessions, each spaced 4 to 6 weeks apart.",[32,125,126],"Breast Cancer","Vulvovaginal Atrophy",[65,128,129,130],"vaginal atrophy","vaginal radiofrequency","breast cancer","2026-03-16",{"date":133,"type":41},"2026-03-18",{"date":135,"type":41},"2025-06-12",{"date":137,"type":22},"2028-06",{"name":139,"class":48},"Centre Oscar Lambret"]